Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity

Genes and Cancer

Volumn 2, Issue 7, 2011, Pages 720-727

  Ru, Peng ^a   Steele, Robert ^a   Hsueh, Eddy C ^a   Ray, Ratna B ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; microRNA 203; SOCS3

Indexed keywords

CASPASE 7; CASPASE 9; CISPLATIN; MICRORNA; MICRORNA 203; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN P21; PROTEIN P53; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 84857411956     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911425832     Document Type: Article

References (42)

1. Ellis LM,Hicklin DJ.VEGF-targeted therapy: mechanisms of anti-tumour activity.Nat Rev Cancer. 2008;8:579-91.
2. Crowder RJ,Phommaly C,Tao Y, et al.PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.Cancer Res. 2009;69:3955-62.
3. Bombonati A,Sgroi DC.The molecular pathology of breast cancer progression.J Pathol. 2011;223:307-17.
4. Ambros V,Lee RC,Lavanway A,Williams PT,Jewell D.MicroRNAs and other tiny endogenous RNAs in C. elegans.Curr Biol. 2003;13:807-18.
5. Bartel DP.MicroRNAs: target recognition and regulatory functions.Cell. 2009;136:215-33.
6. Farazi TA,Spitzer JI,Morozov P,Tuschl T.miRNAs in human cancer.J Pathol. 2011;223:102-15.
7. Trang P,Weidhaas JB,Slack FJ.MicroRNAs as potential cancer therapeutics.Oncogene. 2008;27 (Suppl 2): S52-7.
8. Iorio MV,Croce CM.MicroRNAs in cancer: small molecules with a huge impact.J Clin Oncol. 2009;27:5848-56.
9. Hurst DR,Edmonds MD,Welch DR.Metastamir: the field of metastasis-regulatory microRNA is spreading.Cancer Res. 2009;69:7495-98.
10. Boren T,Xiong Y,Hakam A, et al.MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.Gynecol Oncol. 2009;113:249-55.
11. Xia L,Zhang D,Du R, et al.miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.Int J Cancer. 2008;123:372-79.
12. Hebert C,Norris K,Scheper MA,Nikitakis N,Sauk JJ.High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma.Mol Cancer. 2007;6:5.
13. Moriyama T,Ohuchida K,Mizumoto K, et al.MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance.Mol Cancer Ther. 2009;8:1067-74.
14. Zhou M,Liu Z,Zhao Y, et al.MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.J Biol Chem. 2010;285:21496-507.
15. dit Faute MA,Laurent L,Ploton D,Poupon MF,Jardillier JC,Bobichon H.Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant.Clin Exp Metastasis. 2002;19:161-68.
16. McWhinney SR,Goldberg RM,McLeod HL.Platinum neurotoxicity pharmacogenetics.Mol Cancer Ther. 2009;8:10-6.
17. Smith DD,Saetrom P,Snøve O, et al.Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.BMC Bioinformatics. 2008;9:63.
18. Iorio MV,Visone R,Di Leva G, et al.MicroRNA signatures in human ovarian cancer.Cancer Res. 2007;67:8699-707.
19. Gottardo F,Liu CG,Ferracin M, et al.Micro-RNA profiling in kidney and bladder cancers.Urol Oncol. 2007;25:387-92.
20. Schetter AJ,Leung SY,Sohn JJ, et al.MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.JAMA. 2008;299:425-36.
21. Yde CW,Issinger OG.Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1.Int J Oncol. 2006;29:1397-404.
22. Sangster-Guity N,Conrad BH,Papadopoulos N,Bunz F.ATR mediates cisplatin resistance in a p53 genotype-specific manner.Oncogene. 2011;30:2526-33.
23. Ogata H,Kobayashi T,Chinen T, et al.Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis.Gastroenterology. 2006;131:179-93.
24. Riehle KJ,Campbell JS,McMahan RS, et al.Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3.J Exp Med. 2008;205:91-103.
25. Tischoff I,Hengge UR,Vieth M, et al.Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma.Gut. 2007;56:1047-53.
26. Niwa Y,Kanda H,Shikauchi Y, et al.Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.Oncogene. 2005;24:6406-17.
27. Nakagawa T,Iida S,Osanai T, et al.Decreased expression of SOCS-3 mRNA in breast cancer with lymph node metastasis.Oncol Rep. 2008;19:33-9.
28. Sitko JC,Yeh B,Kim M, et al.SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage.Cell Signal. 2008;20:2221-3.
29. Barclay JL,Anderson ST,Waters MJ,Curlewis JD.SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL.Int J Cancer. 2009;124:1756-66.
30. Lee YS,Dutta A.MicroRNAs in cancer.Annu Rev Pathol. 2009;4:199-227.
31. Hayashita Y,Osada H,Tatematsu Y, et al.A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation.Cancer Res. 2005;65:9628-32.
32. He L,Thomson JM,Hemann MT, et al.A microRNA polycistron as a potential human oncogene.Nature. 2005;435:828-33.
33. Chow TF,Mankaruos M,Scorilas A, et al.The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma.J Urol. 2010;183:743-51.
34. Gabriely G,Wurdinger T,Kesari S, et al.MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators.Mol Cell Biol. 2008;28:5369-80.
35. Corsten MF,Miranda R,Kasmieh R,Krichevsky AM,Weissleder R,Shah K.MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas.Cancer Res. 2007;67:8994-9000.
36. Liu X,Sempere LF,Ouyang H, et al.MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors.J Clin Invest. 2010;120:1298-309.
37. Valastyan S,Reinhardt F,Benaich N, et al.A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis.Cell. 2009;137:1032-46.
38. Saini S,Majid S,Yamamura S, et al.Regulatory role of miR-203 in prostate cancer progression and metastasis.Clin Cancer Res. 2011;17:5287-98.
39. Gebeshuber CA,Zatloukal K,Martinez J.miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis.EMBO Rep. 2009;10:400-5.
40. Li J,Chen Y,Zhao J,Kong F,Zhang Y.miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression.Cancer Lett. 2011;304:52-9.
41. Santi SA,Lee H.Ablation of Akt2 induces autophagy through cell cycle arrest, the downregulation of p70S6K, and the deregulation of mitochondria in MDA-MB231 cells.PLoS One. 2011;6:e14614.
42. Steele R,Mott JL,Ray RB.MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells.Genes Cancer. 2010;1:381-7.